| Literature DB >> 29163950 |
Anahita S Mostaghim1, Hoi Yee Annie Lo1, Nancy Khardori2.
Abstract
OBJECTIVE: This study aims to define risk factors as well as their association with microbiology and clinical outcomes in a large US infective endocarditis population.Entities:
Keywords: Infective endocarditis; epidemiology; hemodialysis; microbiology; mortality; outcomes; risk factor
Year: 2017 PMID: 29163950 PMCID: PMC5692128 DOI: 10.1177/2050312117741772
Source DB: PubMed Journal: SAGE Open Med ISSN: 2050-3121
Trends by age group.
| Total | 18–37 years | 38–57 years | 58–77 years | 78–97 years | p-value | |
|---|---|---|---|---|---|---|
| Total cases | 343 | 37 | 138 | 137 | 31 | |
| 30-day mortality | 71 (20.7%) | 8 (21.6%) | 22 (15.9%) | 38 (27.7%) | 3 (9.7%) | 0.039 |
| 90-day mortality | 90 (26.2%) | 8 (21.6%) | 29 (21.0%) | 49 (35.8%) | 4 (12.9%) | 0.009 |
| 180-day mortality | 100 (29.2%) | 10 (27.0%) | 32 (23.2%) | 53 (38.2%) | 5 (16.1%) | 0.012 |
| Valve surgery | 87 (25.4%) | 8 (21.6%) | 54 (39.1%) | 24 (18.1%) | 1 (3.2%) | <0.001 |
| Embolic phenomena | 104 (29.5%) | 11 (29.7%) | 51 (37.0%) | 36 (26.3%) | 6 (19.4%) | 0.127 |
| Brain | 56 (16.3%) | 5 (13.5%) | 32 (23.2%) | 15 (10.9%) | 4 (12.9%) | 0.043 |
| Pulmonary | 22 (6.4%) | 4 (10.8%) | 9 (6.5%) | 7 (5.1%) | 2 (6.3%) | – |
| Abdominal organs | 20 (5.8%) | – | 12 (8.7%) | 8 (5.8%) | – | – |
| Other location | 30 (8.7%) | 3 (8.1%) | 10 (7.2%) | 17 (12.4%) | – | – |
| 30-day mortality | 19 (18.3%) | 2 (18.2%) | 6 (11.8%) | 10 (27.8%) | 1 (16.7%) | – |
| Causative organism | ||||||
|
| 125 (36.4%) | 19 (51.4%) | 53 (38.4%) | 45 (32.8%) | 8 (25.8%) | 0.109 |
| MRSA | 60 (17.5%) | 5 (13.5%) | 30 (21.7%) | 22 (16.1%) | 3 (9.7%) | 0.303 |
| CoNS | 48 (14.0%) | 4 (10.8%) | 14 (10.1%) | 24 (17.5%) | 6 (19.4%) | 0.244 |
| MR | 23 (6.7%) | 1 (2.7%) | 7 (5.1%) | 13 (9.5%) | 2 (6.3%) | – |
|
| 42 (12.2%) | 2 (5.4%) | 13 (9.4%) | 19 (13.9%) | 8 (25.8%) | 0.041 |
| VGS | 54 (15.7%) | 3 (8.1%) | 25 (18.1%) | 23 (16.7%) | 3 (9.7%) | – |
| Other strep | 31 (9.0%) | 3 (8.1%) | 17 (12.3%) | 9 (6.6%) | 2 (6.3%) | – |
| Other bacteria | 26 (7.6%) | 3 (8.1%) | 11 (8.0%) | 9 (6.6%) | 3 (9.7%) | – |
| Serology positive | 4 (1.2%) | 1 (2.7%) | – | 3 (2.2%) | – | – |
| Fungal | 7 (2.0%) | 3 (8.1%) | 2 (1.5%) | 2 (1.5%) | – | – |
| Valve type affected | ||||||
| Native | 256 (74.6%) | 27 (73.0%) | 106 (76.8%) | 95 (69.3%) | 22 (71.0%) | 0.572 |
| Prosthetic | 63 (18.4%) | 6 (16.2%) | 22 (15.9%) | 30 (21.9%) | 2 (6.5%) | 0.193 |
| Device | 27 (7.9%) | 3 (8.1%) | 7 (5.1%) | 7 (5.1%) | 7 (22.6%) | 0.004 |
MRSA: methicillin-resistant Staphylococcus aureus; CoNS: coagulase-negative Staphylococci; MR: methicillin resistant; VGS: viridans group streptococci.
Percent of total are in parentheses with exception of embolic 30-day mortality which is a percent of embolic phenomena for that age group. Emboli are classified by location.
Risk factor association with mortality, age, valvular surgery, and causative organism.
| CHD | IVDU | CV | PV | ICD | V/S | Hx IE | Dental | IMC | p-value | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total cases | 91 | 34 | 11 | 78 | 70 | 44 | 48 | 29 | 23 | |
| 30-day mortality | 25 (27.5%) | 1 (2.9%) | 2 (18.2%) | 19 (24.4%) | 13 (18.6%) | 9 (20.5%) | 9 (18.8%) | 5 (17.2%) | 5 (21.7%) | 0.242 |
| 90-day mortality | 29 (31.9%) | 3 (8.8%) | 2 (18.2%) | 23 (29.5%) | 18 (25.7%) | 10 (22.7%) | 11 (23.0%) | 7 (24.1%) | 5 (21.7%) | 0.389 |
| 180-day mortality | 35 (38.5%) | 3 (8.8%) | 2 (18.2%) | 24 (31.0%) | 20 (28.6%) | 12 (27.3%) | 13 (27.1%) | 8 (27.6%) | 5 (21.7%) | 0.140 |
| Valve surgery | 14 (15.4%) | 11 (32.4%) | 3 (27.3%) | 18 (23.1%) | 6 (8.6%) | 14 (31.8%) | 18 (37.5%) | 12 (41.4%) | 3 (13.0%) | 0.001 |
| 30-day surgical mortality | 2 (14.2%) | – | – | 4 (22.2%) | 2 (33.3%) | 4 (28.6%) | 2 (11.1%) | 1 (8.3%) | – | |
| Mean age | 55 | 46.5 | 52 | 59 | 65.5 | 53 | 50 | 55 | 57 | < 0.001 |
| Age standard deviation | 12.8 | 12.9 | 14.7 | 13.2 | 15.0 | 17.7 | 11.4 | 10.0 | 15.3 | |
| Age range | 27–83 | 20–68 | 22–71 | 28–83 | 29–89 | 20–86 | 28–67 | 25–67 | 26–84 | |
|
| ||||||||||
|
| 46 (50.5%) | 16 (47.1%) | 5 (45.5%) | 27 (34.6%) | 33 (47.1%) | 12 (27.3%) | 10 (20.8%) | 7 (24.1%) | 5 (21.7%) | 0.005 |
| MRSA | 28 (30.8%) | 9 (26.5%) | 4 (36.4%) | 9 (11.5%) | 12 (17.1%) | 6 (13.6%) | 8 (16.7%) | 6 (20.7%) | 2 (8.7%) | 0.034 |
| CoNS | 25 (27.5%) | – | 2 (18.2%) | 15 (19.2%) | 10 (14.3%) | 6 (13.6%) | 2 (4.2%) | 3 (10.3%) | 6 (26.1%) | 0.003 |
| MR | 9 (9.9%) | – | 2 (18.2%) | 4 (5.1%) | 7 (10.0%) | 2 (4.5%) | – | 1 (3.4%) | 4 (17.4%) | – |
|
| 8 (8.8%) | 2 (5.9%) | 2 (18.2%) | 10 (12.8%) | 10 (14.3%) | 3 (6.8%) | 6 (12.5%) | 3 (10.3%) | 5 (21.7%) | 0.615 |
| VGS | 2 (2.2%) | 10 (29.4%) | – | 7 (9.0%) | 7 (10.0%) | 14 (31.8%) | 4 (8.3%) | 9 (31.0%) | 4 (17.4%) | < 0.001 |
| Other | – | 2 (5.9%) | 1 (7.7%) | 8 (10.3%) | 3 (4.3%) | 1 (2.3%) | 2 (4.2%) | 4 (13.8%) | – | – |
| Other bacteria | 5 (5.5%) | 1 (2.9%) | 1 (9.1%) | 8 (10.3%) | 5 (7.1%) | 4 (9.1%) | 5 (10.4%) | 1 (3.4%) | – | – |
| Fungal | 1 (1.1%) | 2 (5.9%) | 2 (18.2%) | 1 (1.3%) | 1 (1.4%) | – | 2 (4.2%) | – | – | – |
| Serology positive | – | – | – | – | – | 2 (4.5%) | 1 (2.1%) | 1 (3.4%) | 1 (4.3%) | – |
| Valve type affected | ||||||||||
| Native | 74 (81.3%) | 28 (82.4%) | 7 (63.6%) | 20 (25.6%) | 37 (52.9%) | 20 (45.5%) | 26 (54.2%) | 26 (90.0%) | 15 (65.2%) | < 0.001 |
| Prosthetic | 12 (13.2%) | 5 (14.7%) | – | 54 (69.2%) | 3 (4.3%) | 1 (2.3%) | 19 (39.6%) | 5 (17.2%) | 2 (8.7%) | < 0.001 |
| Device | 7 (7.7%) | 2 (5.9%) | 2 (18.2%) | 4 (5.1%) | 23 (32.9%) | 2 (4.5%) | 4 (8.3%) | – | 2 (8.7%) | – |
CHD: chronic hemodialysis; IVDU: intravenous drug use; CV: cardiovascular access; PV: prosthetic valve; ICD: intracardiac device; V/S: native valvular/structural disease; Hx IE: history of infective endocarditis; dental: poor dentition; IMC: immunocompromised; MRSA: methicillin-resistant staphylococcus aureus; CoNS: coagulase-negative Staphylococci; MR: methicillin-resistant; VGS: viridans group streptococci.
Outcomes by causative organism.
|
| CoNS |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| All | MR | All | MR | ETC | VGS | Other strep | Other bacteria | Fungal | p-value | |
| Total cases | 125 | 60 | 48 | 23 | 42 | 54 | 31 | 26 | 7 | |
| 30-day mortality | 29 (23.2%) | 13 (21.7%) | 15 (31.3%) | 7 (30.4%) | 7 (16.7%) | 4 (7.4%) | 7 (22.6%) | 5 (19.2%) | – | 0.060 |
| 90-day mortality | 34 (27.2%) | 17 (28.3%) | 19 (39.6%) | 8 (34.8%) | 7 (16.7%) | 7 (13.0%) | 8 (25.8%) | 7 (26.9%) | – | 0.030 |
| 180-day mortality | 40 (32.0%) | 21 (35.0%) | 19 (39.6%) | 8 (34.8%) | 9 (21.4%) | 7 (13.0%) | 8 (25.8%) | 7 (26.9%) | – | 0.029 |
| Valve surgery | 17 (13.6%) | 6 (10.0%) | 9 (18.8%) | 5 (21.7%) | 7 (16.7%) | 18 (33.3%) | 14 (45.2%) | 6 (23.1%) | 3 (42.9%) | 0.003 |
| Mean age | 55 | 55.5 | 61 | 63 | 62.5 | 56.5 | 53 | 53.5 | 38 | 0.002 |
| Age standard deviation | 15.3 | 14.7 | 14.5 | 13.3 | 15.7 | 11.5 | 12.2 | 16.3 | 14.8 | |
| Age range | 20–89 | 20–89 | 27–83 | 27–83 | 28–90 | 33–88 | 32–81 | 22–86 | 22–65 | |
| Embolic phenomena | 37 (29.6%) | 18 (30.0%) | 14 (29.2%) | 6 (26.1%) | 9 (21.4%) | 21 (38.9%) | 12 (38.7%) | 3 (11.5%) | 6 (86.7%) | 0.004 |
| Brain | 21 (56.8%) | 10 (55.6%) | 8 (57.1%) | 2 (33.3%) | 4 (44.4%) | 10 (47.6%) | 9 (75.0%) | 1 (33.3%) | 1 (16.7%) | 0.215 |
| Pulmonary | 12 (32.4%) | 5 (27.8%) | 1 (7.1%) | 1 (16.7%) | 2 (22.2%) | 6 (28.6%) | – | – | 2 (33.3%) | – |
| Renal/spleen | 4 (10.8%) | 2 (11.1%) | 4 (28.6%) | 2 (33.3%) | 6 (66.7%) | 5 (23.8%) | – | – | 1 (16.7%) | – |
| Other locations | 11 (29.7%) | 4 (22.2%) | 5 (35.7%) | 2 (33.3%) | – | 4 (23.8%) | 4 (33.3%) | 2 (66.7%) | 2 (33.3%) | – |
| Valve type affected | ||||||||||
| Native | 96 (76.8%) | 49 (81.7%) | 34 (70.8%) | 17 (73.9%) | 30 (71.4%) | 44 (81.5%) | 24 (77.4%) | 14 (53.8%) | 3 (42.9%) | 0.073 |
| Prosthetic | 19 (15.2%) | 7 (11.7%) | 10 (20.8%) | 3 (13.0%) | 9 (21.4% | 8 (14.8%) | 5 (16.1%) | 8 (30.8%) | 1 (14.3%) | 0.591 |
| Device | 12 (9.6%) | 5 (8.3%) | 4 (8.3%) | 3 (13.0%) | 3 (7.1%) | 2 (3.8%) | 1(3.2%) | 4 (15.4$) | 2 (28.6%) | – |
CoNS: coagulase-negative staphylococci; MR: methicillin resistant; ETC: enterococcus.
Other streptococci are shown in the column as a subset of streptococcus. Percents of total are in parentheses with exception of percent of embolic phenomena that is a percent of the embolic phenomena per causative organism.